Data insights 18 February 2025 Private US biotechs head for human trials Halda, Accent and Vividion take more projects into phase 1. Read more
Trial results 1 February 2024 Roche perseveres with FAP A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline. Read more
Trial results 18 September 2023 Bayer looks to clinical validation for $1.5bn Vividion deal Read more